Show simple item record

dc.contributor.authorBrady, GC
dc.contributor.authorRoe, JWG
dc.contributor.authorO' Brien, M
dc.contributor.authorBoaz, A
dc.contributor.authorShaw, C
dc.date.accessioned2018-02-20T10:42:03Z
dc.date.issued2018-02
dc.identifier.citationSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018, 26 (2), pp. 515 - 519
dc.identifier.issn0941-4355
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1354
dc.identifier.eissn1433-7339
dc.identifier.doi10.1007/s00520-017-3858-6
dc.description.abstractBackground Dysphagia can occur in advanced lung cancer due to direct tumour invasion or nerve compression. Anti-cancer treatments and co-morbid conditions may also cause or compound dysphagic symptoms. Speech and language therapy (SLT), medical and surgical interventions are available to address dysphagic symptoms in patients with lung cancer, however, management options are not described in national guidelines. Given the potentially short prognoses for patients with lung cancer, the aim of care should be to reduce symptom burden and maximise quality of life (QOL). Central to that aim is the identification and treatment of swallowing difficulties.Purpose This study sought to identify the prevalence and impact of dysphagia on QOL in patients with advanced lung cancer.Methods A single-site, prospective, exploratory study was undertaken. Previously validated patient-reported outcome measures of swallowing were used to identify the presence and impact of dysphagia on QOL: EAT-10 assessment and the SWAL-QOL assessment.Results Seventy-two participants were recruited with 18.1% identified as having dysphagia on completion of the EAT-10 assessment. On further evaluation using the SWAL-QOL, compromised quality of life was noted with increased fatigue and meal time duration, difficulties with food selection and reduced eating desire. Frequent throat clearing, coughing and perceived pharyngeal stasis were reported.Conclusions Dysphagia is a potential symptom in advanced lung cancer which may impact QOL. Patients, carers and healthcare professionals should be aware of this so that early referral to SLT can be expedited. More robust prevalence and interventional studies are required to inform optimal management of this distressing condition.
dc.formatPrint-Electronic
dc.format.extent515 - 519
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectDeglutition Disorders
dc.subjectTerminal Care
dc.subjectPrevalence
dc.subjectProspective Studies
dc.subjectDeglutition
dc.subjectEating
dc.subjectQuality of Life
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectSurveys and Questionnaires
dc.subjectPatient Reported Outcome Measures
dc.titleAn investigation of the prevalence of swallowing difficulties and impact on quality of life in patients with advanced lung cancer.
dc.typeJournal Article
dcterms.dateAccepted2017-08-16
rioxxterms.versionofrecord10.1007/s00520-017-3858-6
rioxxterms.licenseref.startdate2018-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume26
pubs.embargo.termsNot known
icr.researchteamTreatment of thoracic tumoursen_US
dc.contributor.icrauthorO'Brien, Maryen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record